Contact Information: Contact Name: Jelena Aleksic E-mail: jelena.aleksic@pharmenable.com
The Solution The PharmEnable platform combines AI capabilities with deep medicinal chemistry expertise. Originally a spinout from the University of Cambridge, we use the principles of diversity generating methodologies to build up molecular complexity in a small set of steps. PharmEnable’s chemUNIVERSE repository of medicinal chemistry knowledge is a proprietary library of chemical components and strategies collected and coded by our team of medicinal chemists. It enables us to design novel small molecules that are complex and 3-dimensional, and at the same time synthesisable and modifiable. Combining this diversity-oriented approach with chemSAILOR, the AI engine that navigates the possible chemical space of drug-like molecules. chemSAILOR identifies regions of chemical space of interest for a particular disease target, and then uses the knowledge in chemUNIVERSE to populate this region with novel molecules. This gives us a dynamically generated, target-specific library with potentially billions of promising new molecules for tackling the target in question. From there, we use multi-parameter optimisation in order to rapidly zoom in on the brightest stars in those galaxies. Combining diversity generating methodologies at the scale that AI enables results in a powerful engine for designing and developing innovative small molecule drugs across a range of disease areas.
Website: www.pharmenable.com Funding required: £11,000,000 (£6,000,000 already secured)
PharmEnable is an AI drug discovery company mapping unexplored chemical space to develop innovative medicines. Their interdisciplinary approach integrates advanced medicinal chemistry expertise and cutting-edge AI/ computational methods to unlock challenging biological targets. The PharmEnable technology replicates the specificity of biologics in the powerful and scalable form of a small molecule. The Problem While small molecules have been an enormously successful treatment modality in the last century, a lot of existing small molecule collections lack 3-dimensionality and chemical diversity, and only use a small number of known scaffolds. Research shows that more complex and 3-dimensional molecules have fewer side effects and greater chances of making it through clinical trials. In order to tackle drug attrition rates and unlock the next generation of small molecule drugs, we need to be able to more efficiently explore the vast possible chemical space of small molecules, and to identify novel, complex and 3-dimensional molecules with good drug-like properties. To address this Pharmenable has developed an innovative approach to developing new small molecule drugs for oncology and neurology
Made with FlippingBook Learn more on our blog